[1]
|
J. Hinchey, C. Chavez, B. Appignani, J. Breen, L. Pao, A. Wang, et al., “A Reversible Posterior Leukoencephalo- pathy Syndrome,” The New England Journal of Medicine, Vol. 334, No. 8, 1996, pp. 494-500.
doi:10.1056/NEJM199602223340803
|
[2]
|
S. O. Casey, R. C. Sampaio, E. Michel and C. L. Truwit, “Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-Attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions,” Ame- rican Journal of Neuroradiology, Vol. 21, No. 7, 2000, pp. 1199-1206.
|
[3]
|
C. Lamy, C. Oppenheim, J. F. Meder and J. L. Mas, “Neu- roimaging in Posterior Reversible Encephalopathy Syn- drome,” Journal of Neuroimaging, Vol. 4, No. 2, 2004, pp. 89-96.
|
[4]
|
A. R. Pande, K. Ando, R. Ishikura, Y. Nagami, Y. Takada, A. Wada, et al., “Clinicoradiological Factors Influencing the Reversibility of Posterior Reversible Encephalopathy Syndrome: A Multicenter Study,” Radiation Medicine, Vol. 24, No. 10, 2006, pp. 659-668.
doi:10.1007/s11604-006-0086-2
|
[5]
|
T. Kinoshita, T. Moritani, D. A. hrier, A. Hiwatashi, H. Z. Wang, Y. Numaguchi, et al., “Diffusion Weighted MR Imaging of Posterior Reversible Leukoencephalopathy Syndrome: A Pictorial Essay,” Clinical Imaging, Vol. 27, No. 5, 2003, pp. 307-315.
doi:10.1016/S0899-7071(02)00592-2
|
[6]
|
D. Schiff and M. B. Lopes, “Neuropathological Correlates of Reversible Posterior Leukoencephalopathy,” Neurocri- tical Care, Vol. 2, No. 3, 2005, pp. 303-305.
doi:10.1385/NCC:2:3:303
|
[7]
|
A. Norden and T. Batchelor, “Reversible Posterior Leu- koencephalopathy Syndrome after Treatment of Diffuse Large B-Cell Lymphomam” Onkologie, Vol. 30, No. 3, 2007, pp. 90-91.
|
[8]
|
A. Rajasekhar and T. J. George, “Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature,” The Oncolo- gist, Vol. 12, No. 11, 2007, pp. 1332-1335
|
[9]
|
J. De Seze, B. Mastain, T. Stojkovic, D. Ferriby, J. P. Pruvo, A. Destee, et al., “Unusual MR Findings of the Brain in Arterial Hypertension,” American Journal of Neuroradiology, Vol. 21, No. 2, 2000, pp. 391-394.
|
[10]
|
H. Kitaguchi, H. Tomimoto, Y. Miki, A. Yamamoto, K. Terada, H. Satoi, et al., “A Brainstem Variant of Reversi- ble Posterior Leukoencephalopathy Syndrome,” Neurora- diology, Vol. 47, No. 9, 2005, pp. 652-656.
doi:10.1007/s00234-005-1399-z
|
[11]
|
T. Shimono, Y. Miki, H. Toyoda, H. Egawa, S. Uemoto, K. Tanaka, et al., “MR Imaging with Quantitative Diffu- sion Mapping of Tacrolimus-Induced Neurotoxicity in Organ Transplant Patients,” European Radiology, Vol. 13, No. 5, 2003, pp. 986-993.
|
[12]
|
I. J. Berman and M. P. Mann, “Seizures and Transient Cor- tical Blindness Associated with Cis-Platinum (II) Diam- minedichloride (PDD) Therapy in a Thirty-Year-Old Man,” Cancer, Vol. 45, No. 4, 1980, pp. 764-766.
doi:10.1002/1097-0142(19800215)45:4<764::AID-CNCR2820450425>3.0.CO;2-G
|
[13]
|
M. T. Cattaneo, V. Filipazzi, E. Piazza, E. Damiani and G. Mancarella, “Transient Blindness and Seizure Associated with Cisplatin Therapy,” Cancer Research and Clinical Oncology, Vol. 114, No. 5, 1988, pp. 528-530.
doi:10.1007/BF00391507
|
[14]
|
R. N. Hitchins and D. B. Thomson, “Encephalopathy Fol- lowing Cisplatin, Bleomycin and Vinblastine Therapy for non-Seminomatous Germ Cell Tumour of Testis,” Australian and New Zealand Journal of Medicine, Vol. 18, No. 1, 1988, pp. 67-68.
doi:10.1111/j.1445-5994.1988.tb02244.x
|
[15]
|
P. A. Philip, J. Carmichael and A. L. Harris, “Convulsions and transient Cortical Blindness after Cisplatin,” British Medicine Journal, Vol. 302, No. 6773, 1991, p. 416.
doi:10.1136/bmj.302.6773.416
|
[16]
|
M. Highley, S. T. Meller and C. R. Pinkerton, “Seizures and Cortical Dysfunction Following High-Dose Cisplatin Administration in Children,” Medical and Pediatric On- cology, Vol. 20, No. , 1992, pp. 143-148.
doi:10.1002/mpo.2950200210
|
[17]
|
T. Van Gelder, P. Geurs, G. S. Kho, D. W. J. Dippel, Ch. J. Vecht, T. A. W. Splinter, “Cortical Blindness and Sei- zures Following Cisplatin Treatment: Both of Epileptic Origin?” European Journal of Cancer, Vol. 29, No. 10, 1993, pp. 1497-1498. doi:10.1016/0959-8049(93)90030-J
|
[18]
|
D. C. Young, A. Mitchell, J. Kessler and J. E. Christman, “Cortical Blindness and Seizures Possibly Related to Cis- platin, Vinblastine and Bleomycin Treatment of Ovarian Dysgerminoma,” The Journal of the American Osteopathic Association, Vol. 93, No. 2, 1993, pp. 502-504.
|
[19]
|
K. Nomura, R. Ohno, K. Hamaguchi, T. Hata, H. Hatana- ka and H. Matsuyama, “Clinicopathological Report of Cisplatin Encephalopathy,” Rinsho Shinkeigaku, Vol. 35, No. 1, 1995, pp. 64-69.
|
[20]
|
N. Steeghs, F. E. de Jongh, P. A. S. Smitt and M. J. van den Bent, “Cisplatin-Induced Encephalopathy and Sei- zures,” Anti-Cancer Drugs, Vol. 14, No. 6, 2003, pp. 443- 446. doi:10.1097/00001813-200307000-00009
|
[21]
|
P. S. Rangi, W. J. Partridge, E. S. Newlands and A. D. Wald- man, “Posterior Reversible Encephalopathy Syndrome: A Possible Late Interaction between Cytotoxic Agents and General Anaesthesia,” Neuroradiology, Vol. 47, No. 8, 2005, pp. 586-590. doi:10.1007/s00234-005-1376-6
|
[22]
|
O. Lyass, A. Lossos, A. Hubert, M. Gips and T. Peretz, “Cisplatin-Induced Non-Convulsive Encephalopathy,” Anti- Cancer Drugs, Vol. 9, No. 1, 1998, pp. 100-104.
doi:10.1097/00001813-199801000-00013
|
[23]
|
D. M. Pinedo, F. Shah-Khan and P. C. Shah, “Reversible Posterior Leukoencephalopathy Syndrome Associated with Oxaliplatin,” Journal of Clinical Oncology, Vol. 25, No. 33, 2007, pp. 5320-5321. doi:10.1200/JCO.2007.13.5954
|
[24]
|
S. Vieillot, D. Pouessel, N. M. de Champfleur and C. Becht, S. Culine, “Reversible Posterior Leukoencephalopathy Syn- drome after Carboplatin Therapy,” Annals of Oncology, Vol. 18, No. 3, 2007, pp. 608-609.
|
[25]
|
Y Ito, Y Arahata, Y Goto, M Hirayama, M Nagamutsu, T Yasuda, et al., “Cisplatin Neurotoxicity Presenting as Re- versible Posterior Leukoencephalopathy Syndrome,” Ame- rican Journal of Neuroradiology, Vol. 19, No. 3, 1998, pp. 415-417.
|
[26]
|
M. D. Haefner, “Reversible Posterior Leukoencephalo- pathy Syndrome after Treatment of Diffuse Large B-Cell Lymphoma,” Onkologie, Vol. 30, No. 3, 2007, pp. 90-91.
doi:10.1159/000098706
|
[27]
|
G. Martín, L. Bellido and J. J. Cruz, “Reversible Posterior Leukoencephalopathy Syndrome Induced by Sunitinib,” Journal of Clinical Oncology, Vol. 25, No. 23, 2007, p. 3559.
|
[28]
|
C. Ozcan, S. J. Wong and P. Hari, “Reversible Posterior Leucoencephalopathy Syndrome and Bevacizumab,” The New England Journal of Medicine, Vol. 354, No. 9, 2006, pp. 980-982. doi:10.1056/NEJMc052954
|
[29]
|
R. M. Connolly, “Chemotherapy Induced Reversible Post- erior Leukoencephalopathy Syndrome,” Lung Cancer, Vol. 56, No. 3, 2007, pp. 459-463.
doi:10.1016/j.lungcan.2007.01.012
|